Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

被引：8

作者：

Ciccarese, Chiara ^{[1
]}

Montironi, Rodolfo ^{[2
]}

Fiorentino, Michelangelo ^{[3
]}

Martignoni, Guido ^{[4
,5
]}

Brunelli, Matteo ^{[4
]}

Iacovelli, Roberto ^{[1
]}

Lopez-Beltran, Antonio ^{[6
,7
]}

Cheng, Liang ^{[8
]}

Scarpelli, Marina ^{[2
]}

Moch, Holger ^{[9
]}

Tortora, Giampaolo ^{[1
]}

Massari, Francesco ^{[10
]}

机构：

[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy

[2] Polytech Univ Marche Reg, Sch Med, AOU Osped Riuniti, Sect Pathol Anat, Ancona, Italy

[3] St Orsola Marcello Malpighi Hosp, Addarii Inst Oncol, Pathol Serv, Bologna, Italy

[4] Univ Verona, AOUI, Dept Pathol & Diagnost, Verona, Italy

[5] Pederzoli Hosp, Anat Pathol, Verona, Italy

[6] Univ Cordoba, Med Sch, Dept Surg & Pathol, Cordoba, Spain

[7] Champalimaud Clin Ctr, Lisbon, Portugal

[8] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[9] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, Zurich, Switzerland

[10] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy

来源：

CURRENT DRUG METABOLISM | 2017年 / 18卷 / 08期

关键词：

Prostate cancer; mCRPC; circulating tumor cells; CTCs; biomarker; malignancy; INCREASED SURVIVAL; PERIPHERAL-BLOOD; ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; AMPLIFICATION; COUNTS; MARKER;

D O I：

10.2174/1389200218666170518163549

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

引用

页码：692 / 699

页数：8

共 50 条

[11] Detection of circulating tumor cells in different stages of prostate cancer
Thalgott, Mark
Rack, Brigitte
Maurer, Tobias
Souvatzoglou, Michael
Eiber, Matthias
Kress, Veronika
Heck, Matthias M.
Andergassen, Ulrich
Nawroth, Roman
Gschwend, Juergen E.
Retz, Margitta
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (05) : 755 - 763
[12] Circulating tumor cells and advanced prostate cancer
Murez, Thibaut
Droupy, Stephane
Rebillard, Xavier
Alix-Panabieres, Catherine
BULLETIN DU CANCER, 2012, 99 : S4 - S15
[13] Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Scher, Howard I.
Lu, David
Schreiber, Nicole A.
Louw, Jessica
Graf, Ryon P.
Vargas, Hebert A.
Johnson, Ann
Jendrisak, Adam
Bambury, Richard
Danila, Daniel
McLaughlin, Brigit
Wahl, Justin
Greene, Stephanie B.
Heller, Glenn
Marrinucci, Dena
Fleisher, Martin
Dittamore, Ryan
JAMA ONCOLOGY, 2016, 2 (11) : 1441 - 1449
[14] Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer
De Laere, Bram
Oeyen, Steffi
Van Oyen, Peter
Ghysel, Christophe
Ampe, Jozef
Ost, Piet
Demey, Wim
Hoekx, Lucien
Schrijvers, Dirk
Brouwers, Barbara
Lybaert, Willem
Everaert, Els
Van Kerckhove, Piet
De Maeseneer, Daan
Strijbos, Michiel
Bols, Alain
Fransis, Karen
Beije, Nick
de Kruijff, Inge
van Dam, Valerie
Brouwer, Anja
van Dam, Pieter-Jan
Van den Eynden, Gert
Rutten, Annemie
Sleijfer, Stefan
Vandebroek, Jean
Van Laere, Steven
Dirix, Luc
PROSTATE, 2018, 78 (06) : 435 - 445
[15] Prognostic Value of Circulating Tumor Cells in Castration Resistant Prostate Cancer: A Meta-analysis
Zheng, Yuxiao
Zhang, Cheng
Wu, Jie
Cheng, Gong
Yang, Haiwei
Hua, Lixin
Wang, Zengjun
UROLOGY JOURNAL, 2016, 13 (06) : 2881 - 2888
[16] Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients
Theil, Gerit
Fornara, Paolo
Bialek, Joanna
CANCERS, 2020, 12 (12) : 1 - 21
[17] Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naive Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Reichert, Zachery R.
Kasputis, Tadas
Nallandhighal, Srinivas
Abusamra, Sophia M.
Kasputis, Amy
Haruray, Saloni
Wang, Yugang
Williams, Shamara
Singhal, Udit
Alva, Ajjai
Cackowski, Frank C.
Caram, Megan E. V.
Palmbos, Phillip L.
Yentz, Sarah E.
Smith, David C.
Alumkal, Joshi J.
Morgan, Todd M.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
[18] TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Danila, Daniel C.
Anand, Aseem
Sung, Clifford C.
Heller, Glenn
Leversha, Margaret A.
Cao, Long
Lilja, Hans
Molina, Arturo
Sawyers, Charles L.
Fleisher, Martin
Scher, Howard I.
EUROPEAN UROLOGY, 2011, 60 (05) : 897 - 904
[19] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
Sonpavde, Guru
Agarwal, Neeraj
Pond, Gregory Russell
Nagy, Rebecca J.
Nussenzveig, Roberto H.
Hahn, Andrew W.
Sartor, Oliver
Gourdin, Theodore Stewart
Nandagopal, Lakshminarayanan
Ledet, Elisa M.
Naik, Gurudatta
Armstrong, Andrew J.
Wang, Jue
Bilen, Mehmet Asim
Gupta, Shilpa
Grivas, Petros
Pal, Sumanta K.
Lanman, Richard B.
Talasaz, AmirAli
Lilly, Michael B.
CANCER, 2019, 125 (09) : 1459 - 1469
[20] Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer
Todenhoefer, Tilman
Park, Emily Sunyong
Duffy, Simon
Deng, Xiaoyan
Jin, Chao
Abdi, Hamidreza
Ma, Hongshen
Black, Peter C.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (11) : 483.e9 - 483.e16

← 1 2 3 4 5 →